The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Zevra Therapeutics Inc shares valued at $210,908 were sold by McFarlane Neil F. on Oct 10 ’25. At $10.82 per share, McFarlane Neil F. sold 19,500 shares. The insider’s holdings dropped to 222,016 shares worth approximately $2.25 million following the completion of this transaction.
Also, NEIL F MCFARLANE purchased 19,500 shares, netting a total of over 210,990 in proceeds.
Before that, FAVORITO TAMARA A had added 3,175 shares to its account. In a trade valued at $24,718, the Director bought Zevra Therapeutics Inc shares for $7.79 each. Upon closing the transaction, the insider’s holdings increased to 3,175 shares, worth approximately $39485.16.
As published in their initiating research note from H.C. Wainwright on July 02, 2025, Zevra Therapeutics Inc [ZVRA] has been a Buy and the price target has been revised to $26. As of October 07, 2024, Guggenheim has initiated its “Buy” rating for ZVRA. Earlier on September 24, 2024, Maxim Group resumed its rating. Their recommendation was “a Buy” for ZVRA stock.
Analyzing ZVRA Stock Performance
On last trading session, Zevra Therapeutics Inc [NASDAQ: ZVRA] rose 0.20% to $10.14. The stock’s lowest price that day was $10.032, but it reached a high of $10.53 in the same session. During the last five days, there has been a drop of approximately -5.06%. Over the course of the year, Zevra Therapeutics Inc shares have jumped approximately 25.96%. Shares of the company reached a 52-week high of $13.16 on 07/15/25 and a 52-week low of $6.19 on 04/09/25.
Support And Resistance Levels for Zevra Therapeutics Inc (ZVRA)
According to the 24-hour chart, there is a support level at 9.94, which, if violated, would cause prices to drop to 9.74. In the upper region, resistance lies at 10.44. The next price resistance is at 10.73. RSI (Relative Strength Index) is 47.73 on the 14-day chart, showing neutral technical sentiment.
Is Zevra Therapeutics Inc subject to short interest?
Stocks of Zevra Therapeutics Inc saw a sharp rise in short interest on 2025-10-15 jumping by 0.59 million shares to 7.99 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 7.4 million shares. A jump of 7.4% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.96 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.96.
Which companies own the most shares of Zevra Therapeutics Inc (ZVRA)?
In terms of Zevra Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 21.5 in the next 12 months, up nearly 112.45% from the previous closing price of $10.12. Analysts anticipate Zevra Therapeutics Inc stock to reach 25 by 2025, with the lowest price target being 18. In spite of this, 7 analysts ranked Zevra Therapeutics Inc stock as Buy at the end of 2025. On September 24, 2024, JMP Securities assigned a price target of “a Mkt outperform” to the stock and initiated coverage with a $17.
